
NTHI Stock Forecast & Price Target
NTHI Analyst Ratings
Bulls say
NeOnc Technologies Hldgs is a biotech company with a strong focus on developing innovative treatments for brain tumors. Its lead drug, NEO212, has shown promising results in clinical trials and the company's financials have improved. With the potential success of NEO100 and the use of Perillyl Alcohol, NeOnc has a solid opportunity to improve the treatment options for patients with difficult-to-treat central nervous system diseases.
Bears say
NeOnc Technologies Hldgs is facing potential technical risks with its complex drug dosing, potentially causing delays in its pipeline molecules reaching the market. Furthermore, the company's drugs may have potential safety risks for patients due to chronic disruption of nasal epithelial integrity. The company's data for its lead candidates is limited, and the slow enrollment in clinical trials may delay potential market entry. Overall, it remains to be seen if the company's drug delivery methods can prove effective in penetrating the CNS and achieving positive clinical outcomes, and more comprehensive data is needed for a clearer outlook on the company's potential.
This aggregate rating is based on analysts' research of Neonc Technologies Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
NTHI Analyst Forecast & Price Prediction
Start investing in NTHI
Order type
Buy in
Order amount
Est. shares
0 shares